Paul Hastings LLP advised Xencor, Inc. on the offering. Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and...
You must be a Standard 1 Year member to access this content.
Paul Hastings represented Seaport Global Acquisition II Corp. in the business combination. Seaport Global Acquisition II Corp. (NASDAQ: SGII), a publicly-listed special purpose acquisition company, and...
You must be a Standard 1 Year member to access this content.
Jones Day advised Horizon Global on the deal while Paul Hastings LLP advised First Brands Group. Horizon Global Corporation (NYSE: HZN), one of the world’s leading...
You must be a Standard 1 Year member to access this content.
